COST-EFFECTIVENESS ANALYSIS OF THE ONCOTYPE DX BREAST RECURRENCE SCORE® TEST FOR POSTMENOPAUSAL WOMEN WITH HR+/HER2-NODE-POSITIVE EARLY BREAST CANCER IN CANADA

被引：0
|
作者：
Berdunov, V [1 ]
Richardson, R. [2 ]
Millen, S. [3 ]
机构：
[1] PHMR Ltd, London, England
[2] Exact Sci, Dartmouth, NS, Canada
[3] Exact Sci, London, England
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE194
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF ALPELISIB PLUS FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH PIK3CA MUTANT, HR+/HER2-ADVANCED BREAST CANCER IN TURKEY
    Tatar, M.
    Akgul, T.
    Ozbalas, T.
    Yuzgenc, Z.
    Cilingiroglu, M.
    VALUE IN HEALTH, 2022, 25 (12) : S133 - S133
  • [42] Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2-metastatic breast cancer in postmenopausal women in Panama
    Castillo-Fernandez, Omar O.
    Lim, Maria
    Montano, Lilian
    CANCER RESEARCH, 2023, 83 (05)
  • [43] COST-EFFECTIVENESS ANALYSIS OF ADJUVANT ANASTROZOL IN POSTMENOPAUSAL WOMEN WITH BREAST CANCER
    Sasse, Andre Deeke
    Sasse, Emma Chen
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2009, 55 (05): : 535 - 540
  • [44] Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)
    Abu-Khalaf, Maysa M.
    Aderhold, Kimberly
    Marczyk, Michal
    Chung, Gina
    Hofstatter, Erin
    Sanft, Tara
    Silber, Andrea
    DiGiovanna, Michael
    Zelterman, Daniel
    Puzstai, Lajos
    Hatzis, Christos
    CANCER RESEARCH, 2020, 80 (04)
  • [45] Utility of oncotype in premenopausal women with hormonal receptor (hr) positive her2 negative early breast cancer
    Cudos, A. Gasol
    Murillo, S. Morales
    Der-Abrain, N. Tuset
    Guzman, D. R. Sanchez
    Villellas, F. Vilardell
    Orillo, E. Morera M.
    Morales, C. Canosa
    Olive, J. Mele
    Cid, L. Arbones
    BREAST, 2023, 68 : S19 - S19
  • [46] Breast cancer specific survival in patients with node-positive hormone receptor positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database
    Roberts, Megan
    Petkov, Valentina I.
    Miller, Dave P.
    Shak, Steven
    Howlader, Nadia
    Cronin, Kathleen
    Penberthy, Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] COST-EFFECTIVENESS ANALYSIS OF RIBOCICLIB VERSUS ABEMACICLIB IN THE FIRST-LINE (1L) TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER (ABC)
    Cameron, D.
    Sharma, V.
    Biswas, C.
    Clarke, C.
    Chandiwana, D.
    Pathak, P.
    VALUE IN HEALTH, 2022, 25 (12) : S126 - S126
  • [48] Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score
    Meisel, Jane
    Zhang, Chao
    Neely, Cameron
    Menduza, Pia
    You, Shuo
    Han, Tatiana
    Liu, Yuan
    Sahin, Aysegul A.
    O'Regan, Ruth
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2018, 18 (05) : 347 - 352
  • [49] Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer
    Sestak, Ivana
    Ferree, Sean
    Shemesh, Itay
    Buckingham, Wesley
    Cuzick, Jack
    Dowsett, Mitchell
    CANCER RESEARCH, 2020, 80 (04)
  • [50] Cost-effectiveness analysis of Mammostrat (R) compared with Oncotype DX (R) to inform the treatment of breast cancer
    Mislick, Kimberly
    Schonfeld, Warren
    Bodnar, Carolyn
    Tong, Kuo Bianchini
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2014, 6 : 37 - 47
12345